Drugs / MF1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07666022 | Jun 2026 → Sep 2028 expected | Parkinson disease | University of Shizuoka | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MF1 | “MF1 is a novel investigational agent designed to target the pathophysiological mechanisms underlying α-synucleinopathy.” NCT07666022 ↗ |
| Action | Inhibit | “MF1 inhibits α-synuclein aggregation” NCT07666022 ↗ |
| Route | Oral | “Oral administration of MF1” NCT07666022 ↗ |